Mumbai, July 26, 2025 — A recent randomized comparative study conducted at Corion Fertility Clinic, Mumbai, has found that Pergoveris (rFSH + rLH in a 2:1 ratio) may offer superior clinical pregnancy outcomes and embryo development in women above the age of 38 with diminished ovarian reserve (AMH <1.2 ng/mL), compared to Gonal F (rFSH).
The study, conducted over two years with 297 self IVF/ICSI patients, revealed that Pergoveris showed higher day 5 blastocyst rates, fewer germinal vesicle oocytes, and a reduction in biochemical pregnancies. Notably, women above 38 years of age in the Pergoveris group had a 63% pregnancy rate, compared to 37% in the Gonal F group.
Patients were divided into two cohorts—Group A (Gonal F, n=144) and Group B (Pergoveris, n=153)—with comparable profiles based on age and AMH. The results underline the importance of age-specific and individualized ovarian stimulation protocols, especially in women classified under Poseidon Group 4, who typically show poor prognosis in ART cycles.
Quote by Dr. Kaushal Kadam, MBBS, MD, DGO and Director, Corion Fertility Clinic Pvt Ltd, “As clinicians, we constantly seek ways to optimize outcomes for women with low ovarian reserve. Our findings suggest that LH supplementation through Pergoveris meaningfully improves embryo quality and pregnancy rates, particularly in women above 38 years. This study reinforces the value of personalized protocols in assisted reproduction and highlights the critical role of age and AMH in treatment planning.”
Despite some limitations—including its single-center design and relatively small sample size—the study offers promising insights that warrant larger, multi-centric trials to validate the broader clinical utility of LH supplementation in IVF.